146 related articles for article (PubMed ID: 29618479)
1. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.
Statler A; Othus M; Erba HP; Chauncey TR; Radich JP; Coutre S; Advani A; Nand S; Ravandi F; Mukherjee S; Sekeres MA
Blood; 2018 Jun; 131(25):2782-2788. PubMed ID: 29618479
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
4. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
Somer RA; Sherman E; Langer CJ
Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
[TBL] [Abstract][Full Text] [Related]
5. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.
Peixoto RD; Ho M; Renouf DJ; Lim HJ; Gill S; Ruan JY; Cheung WY
Am J Clin Oncol; 2017 Oct; 40(5):507-511. PubMed ID: 25844823
[TBL] [Abstract][Full Text] [Related]
6. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes of advanced melanoma patients not represented in phase III trials.
van Zeijl MCT; Ismail RK; de Wreede LC; van den Eertwegh AJM; de Boer A; van Dartel M; Hilarius DL; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Haanen JBAG; Wouters MWJM
Int J Cancer; 2020 Dec; 147(12):3461-3470. PubMed ID: 32559817
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
9. Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.
Lin L; Smit EF; de Langen AJ; van Balen DEM; Beijnen JH; Huitema ADR
Target Oncol; 2022 Jan; 17(1):53-59. PubMed ID: 34894319
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
Malatestinic W; Nordstrom B; Wu JJ; Goldblum O; Solotkin K; Lin CY; Kistler K; Fraeman K; Johnston J; Hawley LL; Sicignano N; Araujo A
J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
[TBL] [Abstract][Full Text] [Related]
11. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
13. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
15. Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma.
Flaherty LE; Liu PY; Unger J; Sondak VK
Am J Clin Oncol; 1997 Dec; 20(6):600-4. PubMed ID: 9391549
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.
Fujimoto D; Morimoto T; Tamiya M; Hata A; Matsumoto H; Nakamura A; Yokoyama T; Taniguchi Y; Uchida J; Sato Y; Yokoi T; Tanaka H; Furuya N; Masuda T; Sakata Y; Miyauchi E; Hara S; Saito G; Miura S; Kanazu M; Yamamoto N; Akamatsu H
JAMA Netw Open; 2023 Feb; 6(2):e230698. PubMed ID: 36826813
[TBL] [Abstract][Full Text] [Related]
18. Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
Al-Baimani K; Jonker H; Zhang T; Goss GD; Laurie SA; Nicholas G; Wheatley-Price P
Curr Oncol; 2018 Aug; 25(4):e291-e297. PubMed ID: 30111974
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
Pond GR; Agarwal A; Ornstein M; Garcia J; Gupta R; Grivas P; Drakaki A; Lee JL; Kanesvaran R; Lorenzo GD; Verolino P; Barata P; Bilen MA; Hussain SA; Curran C; Sonpavde G
Clin Genitourin Cancer; 2021 Oct; 19(5):425-433. PubMed ID: 34006497
[TBL] [Abstract][Full Text] [Related]
20. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]